1. Home
  2. CRSP vs IDCC Comparison

CRSP vs IDCC Comparison

Compare CRSP & IDCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • IDCC
  • Stock Information
  • Founded
  • CRSP 2013
  • IDCC 1972
  • Country
  • CRSP Switzerland
  • IDCC United States
  • Employees
  • CRSP N/A
  • IDCC N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • IDCC Multi-Sector Companies
  • Sector
  • CRSP Health Care
  • IDCC Miscellaneous
  • Exchange
  • CRSP Nasdaq
  • IDCC Nasdaq
  • Market Cap
  • CRSP 4.0B
  • IDCC 4.6B
  • IPO Year
  • CRSP 2016
  • IDCC N/A
  • Fundamental
  • Price
  • CRSP $47.25
  • IDCC $182.07
  • Analyst Decision
  • CRSP Buy
  • IDCC Hold
  • Analyst Count
  • CRSP 19
  • IDCC 3
  • Target Price
  • CRSP $73.69
  • IDCC $120.00
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • IDCC 450.6K
  • Earning Date
  • CRSP 11-05-2024
  • IDCC 10-31-2024
  • Dividend Yield
  • CRSP N/A
  • IDCC 0.99%
  • EPS Growth
  • CRSP N/A
  • IDCC 28.72
  • EPS
  • CRSP N/A
  • IDCC 9.29
  • Revenue
  • CRSP $202,829,000.00
  • IDCC $721,232,000.00
  • Revenue This Year
  • CRSP N/A
  • IDCC $59.60
  • Revenue Next Year
  • CRSP $526.27
  • IDCC N/A
  • P/E Ratio
  • CRSP N/A
  • IDCC $19.59
  • Revenue Growth
  • CRSP 19.31
  • IDCC 28.53
  • 52 Week Low
  • CRSP $43.42
  • IDCC $95.33
  • 52 Week High
  • CRSP $91.10
  • IDCC $191.57
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.94
  • IDCC 70.84
  • Support Level
  • CRSP $50.60
  • IDCC $145.29
  • Resistance Level
  • CRSP $59.07
  • IDCC $191.57
  • Average True Range (ATR)
  • CRSP 2.84
  • IDCC 6.98
  • MACD
  • CRSP -0.35
  • IDCC 1.49
  • Stochastic Oscillator
  • CRSP 7.48
  • IDCC 79.83

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

About IDCC InterDigital Inc.

InterDigital Inc is a research and development company focused on wireless, video, Artificial Intelligence and related technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, Out of which the majority is from the China.

Share on Social Networks: